Home Sectors Healthcare Latest Valuation: Cambrex Corporation (NYSE: CBM)

Latest Valuation: Cambrex Corporation (NYSE: CBM)

39
0
SHARE

Cambrex Corporation is part of the biotechnology industry and is in the healthcare sector. The company CEO is Steven M. Klosk. Cambrex Corp is a biotechnology company focused on developing and commercializing new and generic therapeutics. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.

Previous Intraday Trading Performance:

The CBM stock showed a previous change of -1.05% with an open at 39.00 and a close of 38.60. It reached an intraday high of 39.39 and a low of 38.43.

SeekingAlpha:  Nomura bearish on Xencor in premarket analyst action

Liquidity:

The stock has a market cap of $1.3b with 33.7m shares outstanding, of which the float is 32.6m shares. Trading volume reached 293,225 shares compared to its average volume of 544,363 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Cambrex Corporation shares returned -2.28% and in the past 30 trading days it returned -6.65%. Over three months, it changed 1.63%. In one year it has changed -28.52% and within that year its 52-week high was 69.43 and its 52-week low was 33.80. CBM stock is 14.20% above its 52 Week Low.

Our calculations show a 200 day moving average of 51.30 and a 50 day moving average of 41.32. Currently CBM stock is trading -24.76% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Nomura bearish on Xencor in premarket analyst action

Earnings:

The last annual fiscal EPS for the company was reported at 2.76 that ended on 31st of December 2018, which according to the previous close, that is a PE of 14.04. Based on 1 analyst estimate, the estimated EPS for the next quarter is 1.32. The TTM EPS is 2.76, which comes to a TTM PE of 13.99. Historically, the PE high was 33.80 and the PE low was 11.70. If the stock reached its PE low, that would represent a price of 32.28, which is a decrease of -16.37%.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.04
09-30-2018:  0.79
06-30-2018:  1.21
03-31-2018:  0.72

Base on our calculations, the intrinsic value per share is 42.52, which means it is possibly undervalued and has a margin of safety of 9.21%

Indicators to Watch:

Based on the latest filings, there is 3.10% of insider ownership and 175.00% of institutional ownership. Short-interest is 4,197,225, which is 12.47% of shares outstanding. The short-interest ratio or days-to-cover ratio is 7.39. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

The current calculated beta is 2.41

Business Wire:  Caleres Elects Lisa Flavin to Board of Directors

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 15.42%, return on assets is 9.41%, profit margin is 17.95%, price-to-sales is 2.55 and price-to-book is 2.01.

Company Scores:

All scores are out of six:
 3  :Valuation Score
 2  :Past Performance Score
 3  :Financial Strength Score
 0  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.